BRIEF-Biogen - To Continue To Urge CMS To Align Medicare Coverage For Class Of Amyloid-Directed Therapies With Populations Studied In Respective Clinical Trials, For Appropriate Use


Reuters | Updated: 12-01-2022 16:26 IST | Created: 12-01-2022 16:26 IST
BRIEF-Biogen - To Continue To Urge CMS To Align Medicare Coverage For Class Of Amyloid-Directed Therapies With Populations Studied In Respective Clinical Trials, For Appropriate Use

Biogen Inc:

* BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE

* BIOGEN - COVERAGE WITH EVIDENCE DEVELOPMENT (CED) UNDER A RANDOMIZED CLINICAL TRIAL WILL EXCLUDE ALMOST ALL ALZHEIMER’S PATIENTS WHO MAY BENEFIT Source text for Eikon: Further company coverage:

Also Read: U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback